SAMİ AKBULUT, MURAT HARPUTLUOGLU, SEZAİ YİLMAZ
Experimental and Clinical Transplantation - 2018;16(5):635-637
The risk of de novo hepatitis B virus infection is lower after liver transplant using hepatitis B core antibody-negative donors into negative recipients versus hepatitis B core antibody-positive donors but can occur. Here, we present a 34-year-old male patient with acute de novo hepatitis B virus that developed 7 months after successful liver transplant. The case we report here is the first in the literature with regard to both switch from tenofovir to entecavir treatment and the presentation of de novo acute hepatitis B virus after liver transplant. The switch in treatment protocol resulted in significant improvements in serologic and biochemical levels, and the patient was discharged hospital on day 35 after admittance.
